aMAP Risk Score and Mortality in MASLD/MetALD/ALD Patients: NHANES Cohort Study

A cohort study of 32,654 participants from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018, investigating the association between the aMAP risk score and mortality in patients with steatotic liver disease. The dataset was authored by Peng-yang Li and last updated in April 2026. It includes results from multivariable Cox models and Kaplan-Meier analyses for all-cause, cardiovascular, and cancer mortality.

Use Cases

• Validating the aMAP score as a non-invasive risk-stratification tool based on the described cohort analysis.
• Modeling non-linear mortality relationships using restricted cubic spline analysis as mentioned in the description.
• Conducting subgroup survival analysis for MASLD, MetALD, and ALD patient classifications referenced in the results.
• Performing external validation of biomarker associations using a separate hospital-based cohort described in the methods.

Strengths

• Includes a large primary cohort of 32,654 participants from a national survey (NHANES).
• Provides external validation using an independent hospital-based cohort of 642 individuals.
• Analyses multiple mortality outcomes: all-cause, cardiovascular, and cancer.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (24.7 KB), suggesting it may contain summary results rather than raw patient-level data.

Provenance

Source

National Health and Nutrition Examination Survey (NHANES) and an independent hospital-based Southern Chinese cohort.

Collection Method

Cohort study using multivariable Cox proportional hazards models, restricted cubic spline analysis, and Kaplan-Meier curves.

Time Range

NHANES data from 1999 to 2018, with mortality follow-up through December 31, III.

Freshness

Last updated 2026-04-24 13:49:21; freshness should be verified.

Geography

United States (NHANES) and Southern China (validation cohort).